Advertisement
Advertisement
U.S. Markets open in 1 hr 32 mins
Advertisement
Advertisement
Advertisement
Advertisement

Clearmind Medicine Inc. (CMNDF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.5612-0.1338 (-19.26%)
At close: 3:58PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6950
Open0.5595
BidN/A x N/A
AskN/A x N/A
Day's Range0.5595 - 0.5612
52 Week Range0.5500 - 0.7300
Volume1,500
Avg. Volume2,608
Market CapN/A
Beta (5Y Monthly)1.81
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Clearmind Medicine Launches Study for Binge Eating with The Hebrew University Using its Proprietary MEAI Compound

    Focus on the discovery and development of novel therapeutic strategies to treat obesity and its related metabolic disorders TORONTO, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF), (“Clearmind” or the “Company”), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce it has signed an agreement to fund a

  • GlobeNewswire

    Clearmind Medicine to Pursue Dual Listing on Nasdaq

    Toronto, Ontario, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF), (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announced that its board of directors has decided to pursue a dual listing on the Nasdaq Stock Market. Clearmind intends to file a registration statements with the U.S.

  • Newsfile

    Clearmind Medicine Engages Bar-Ilan University to Evaluate Anti-Addictive Properties of Clearmind's Proprietary MEAI Compound

    Professor Gal Yadid, renowned neuropsychopharmacologist, to spearhead the project Toronto, Ontario--(Newsfile Corp. - November 18, 2021) - Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (OTC Pink: CMNDF) ("Clearmind" or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announces it has signed an R&D agreement with Professor Gal Yadid from the Gonda

Advertisement
Advertisement